Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) will report fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before the U.S. market opens. Management will host a conference call and live webcast at 8:30 am ET that day to discuss results and provide a business update.

According to the company, the live webcast is available at the provided webcast link and a replay will be accessible for at least 30 days on the Investors section of the company website.

News Market Reaction – KRYS

-0.70%

1 alert

-0.70% News Effect

On the day this news was published, KRYS declined 0.70%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: February 17, 2026 Conference call time: 8:30 am ET Webcast replay duration: 30 days

3 metrics

Earnings release date February 17, 2026 Scheduled fourth quarter and full year 2025 results

Conference call time 8:30 am ET Earnings call and business update on February 17, 2026

Webcast replay duration 30 days Replay available on company website

Market Reality Check

Price: $274.59 Vol: Volume 249,460 vs 20-day ...

normal vol

$274.59 Last Close

Volume Volume 249,460 vs 20-day average 300,763 (relative volume 0.83) ahead of the earnings date announcement. normal

Technical Shares at $272.61, trading above 200-day MA of $182.74, within -7.9% of the 52-week high.

Peers on Argus

KRYS was nearly flat (-0.05%) while peers showed mixed moves (e.g., ARWR -3.26%,...

KRYS was nearly flat (-0.05%) while peers showed mixed moves (e.g., ARWR -3.26%, ACLX +1.86%), suggesting stock-specific positioning rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Clinical update	Positive	+1.0%	Positive interim KB407 Phase 1 CORAL-1 data in cystic fibrosis patients.
Jan 07	Clinical call notice	Neutral	-1.2%	Announcement of investor call to share interim CORAL-1 KB407 clinical data.
Jan 05	Conference participation	Neutral	-0.9%	Participation and presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Nov 26	Conference participation	Neutral	+0.8%	Presentation and investor meetings at the 8th Annual Evercore Healthcare Conference.
Nov 03	Earnings release	Positive	+0.2%	Third quarter 2025 financial and operating results including VYJUVEK revenue growth.

Pattern Detected

Recent news events, including clinical updates and conferences, have been followed by relatively modest one-day price moves, with no clear pattern of sharp divergence from the apparent news tone.

Recent Company History

Over the past several months, KRYS has reported multiple updates across clinical, corporate, and financial fronts. A positive interim KB407 Phase 1 CORAL-1 update on Jan 8, 2026 was associated with a modest +1.03% move. Conference participation in early 2026 and late 2025 saw small price changes around 1% or less. Third quarter 2025 financial results on Nov 3, 2025 also produced a limited +0.17% reaction. Against this backdrop, today’s earnings-date announcement fits into a pattern of information-driven but measured trading responses.

Market Pulse Summary

This announcement sets expectations for Krystal Biotech’s fourth quarter and full year 2025 earnings...

Analysis

This announcement sets expectations for Krystal Biotech’s fourth quarter and full year 2025 earnings release and accompanying call on February 17, 2026. Recent history shows the stock has responded modestly to clinical, conference, and earnings updates, with one-day moves generally near 1%. Ahead of the call, investors may focus on how final audited 2025 figures compare with previously furnished preliminary numbers and on any updated guidance or pipeline timelines discussed.

AI-generated analysis. Not financial advice.

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

FAQ

When will Krystal Biotech (KRYS) report Q4 and full year 2025 results?

Krystal Biotech will report Q4 and full year 2025 results on February 17, 2026 before the U.S. market opens. According to the company, management will present a conference call and webcast at 8:30 am ET to review the results and business update.

What time is the Krystal Biotech (KRYS) earnings webcast on February 17, 2026?

The company will host the live webcast and conference call at 8:30 am ET on February 17, 2026. According to the company, the webcast will cover fourth quarter and full year 2025 results and include management commentary and Q&A for investors.

How can investors access the Krystal Biotech (KRYS) live webcast for the February 17, 2026 results?

Investors can access the live webcast via the company's provided webcast URL. According to the company, the link is available for live listening and the event will include management remarks and a question-and-answer session for investors.

Will Krystal Biotech (KRYS) provide a replay of the February 17, 2026 webcast, and for how long?

Yes. According to the company, a replay of the webcast will be available on the Investors section of the company website for at least 30 days after the event. The replay allows investors who missed the live call to review the results and discussion.

What will Krystal Biotech (KRYS) discuss during the February 17, 2026 conference call?

The conference call will discuss fourth quarter and full year 2025 financial results and provide a business update. According to the company, management will review performance metrics, operational highlights, and respond to investor questions during the call.

Where is the Krystal Biotech (KRYS) replay hosted after the February 17, 2026 earnings call?

The replay will be hosted on the Investors section of the company website for at least 30 days. According to the company, the investor relations site will provide access to the webcast recording and any supplemental presentation materials.